AstraZeneca PLC (AZN)vsOSR Holdings Inc (OSRH)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
OSRH
OSR Holdings Inc
$0.42
-1.12%
HEALTHCARE · Cap: $14.13M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2299185% more annual revenue ($60.44B vs $2.63M). AZN leads profitability with a 17.2% profit margin vs 0.0%. OSRH trades at a lower P/E of 13.4x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
OSRH
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for OSRH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -14.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : OSRH
The strongest argument for OSRH centers on Price/Book, Debt/Equity, P/E Ratio.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : OSRH
The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while OSRH is a value play — different risk/reward profiles.
OSRH carries more volatility with a beta of 0.61 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
OSR Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
OSR Holdings Inc. is a prominent provider of integrated managed services, specializing in asset management and financial advisory solutions tailored for institutional clients. Leveraging cutting-edge technology and strategic collaborations, the company enhances operational efficiency while expanding its diverse service portfolio. Committed to sustainable growth and client-centric value creation, OSR Holdings distinguishes itself through innovation and exceptional service quality. With a proactive approach to emerging market opportunities, the firm upholds a robust risk management framework, ensuring long-term stability and success for its stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?